Medicure Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Albert David Friesen
- Full Time Employees
- 23
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2-1250 Waverley Street Winnipeg MB Canada R3T 6C6
- IPO Date
- Feb 19, 2004
- CIK
- 0001133519
- Website
- medicure.com
- Similar Companies
- Business
- Medicure Inc. (TSXV:MPH; OTC:MCUJF) is a pharmaceutical company focused on the development and commercialization of cardiovascular therapeutics and healthcare products for the U.S. market. The company markets and distributes AGGRASTAT (tirofiban hydrochloride) injection, a glycoprotein IIb/IIIa inhibitor used in cardiac catheterization labs to reduce thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome; ZYPITAMAG (pitavastatin) tablets, an HMG-CoA reductase inhibitor statin approved by the U.S. Food and Drug Administration in 2017 for lowering cholesterol; sodium nitroprusside injection, an acute care cardiovascular drug; and BRENZAVVY, offered through its integrated e-commerce platform for direct online ordering and home delivery to patients and providers. Medicure operates Marley Drug Inc., a direct-to-consumer pharmacy servicing all 50 U.S. states, Washington D.C., and Puerto Rico, with a commitment to improving medication access and adherence; it also pursues its pipeline of pyridoxal 5'-phosphate analogues (P5P Analogues). Founded in 1997 and headquartered in Winnipeg, Manitoba, Canada, the company conducts its U.S. operations through wholly-owned subsidiaries including Medicure Pharma Inc., Medicure USA Inc., and Medicure International Inc. (Barbados), targeting physicians, healthcare professionals, hospitals, and patients in the cardiovascular and specialty pharmaceutical segments. In recent developments, Medicure expanded its pharmacy business through the acquisition of Gateway Medical Pharmacy and the closing of its purchase of West Olympia Pharmacy Inc. in June 2025 for USD $975,000, adding approximately $10 million in projected annual net revenue to accelerate ZYPITAMAG and BRENZAVVY sales while enhancing patient access; the company also signed an asset purchase agreement in August 2025 with CanAm Bioresearch Inc. to acquire intellectual property supporting its growth strategy.
Medicure Inc. (MPH:CA) Q1 2026 Earnings Call Prepared Remarks Transcript
Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Medicure Announces AGM Results and Appointment of New Director
Medicure Inc. (MPH:CA) Q4 2025 Earnings Call Prepared Remarks Transcript
Medicure (OTCMKTS:MCUJF) and Wellgistics Health (NASDAQ:WGRX) Head to Head Analysis
Medicure Announces Resignation of President and Chief Operating Officer
Medicure (OTCMKTS:MCUJF) Share Price Crosses Above 50 Day Moving Average – Here’s Why
Medicure Inc. (MPH:CA) Q3 2025 Earnings Call Transcript
Medicure Reports Financial Results for Quarter Ended September 30, 2025
Medicure To Present Financial Results on November 20, 2025 Call at 8:30 AM ET for Quarter Ended September 30, 2025
Medicure Reports Financial Results for Quarter Ended June 30, 2025
Medicure to Present Financial Results on August 21, 2025 Call at 8:30 am ET for Quarter Ended June 30, 2025
Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia Pharmacy
Medicure Reports Financial Results for Quarter Ended March 31, 2025 and Annual General Meeting Director Election Results
Medicure Inc. (MCUJF) Q4 2024 Earnings Call Transcript
Medicure to Present Financial Results on April 29, 2025 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2024
Medicure Announces Further Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of West Olympia Pharmacy
Medicure Announces Closing of Purchase Agreement for the Acquisition of Gateway Medical Pharmacy
Medicure Announces Expansion of Its Pharmacy Business Through Signing of a Purchase Agreement for the Acquisition of Gateway Medical Pharmacy
Medicure Reports Financial Results For Quarter Ended September 30, 2024